NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ASTRAZEN · data 2026-11-01
AstraZeneca Pharma India Limited
In plain words
Price: 35.4% below its 52-week high of ₹9,849.5.
Delivery: 51.0% of traded shares were kept for delivery over the last 10 sessions, against 53.8% over the last 60.
Latest results: a net profit of ₹38 cr for the quarter ended Jun 2026 (-32.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,432 cr |
| Net profit (last 12 months) | ₹170 cr |
| Sales growth, 3 years (yearly) | 31.4% |
| Profit growth, 3 years (yearly) | 23.6% |
At a glance
Promoters 75.0% (unchanged in a year), pledged 0.0%, institutions 9.7%.
P/E 93.8, dividend yield 0.6%. Price relative to earnings and book value (low is cheaper, not better).
ROE 23.9%, ROCE 25.5%, operating margin 9.9%: how much profit it earns on the money it uses.
Debt/equity 0.13, Profit growth 23.6% and sales growth 31.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (23.9%).
- Profit grew 23.6% a year over 3 years.
- Expensive on earnings (P/E 93.8).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ASTRAZEN Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹682.79 crore, up 29.7% YoY and up 18% QoQ.
Net profit was ₹37.93 crore, down 32.1% YoY and down 15.5% QoQ.
Operating margin was 7.2% (15.4% a year ago).
EPS was ₹15.17, down 32.1% YoY and down 15.5% QoQ.
ASTRAZEN के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹682.79 करोड़; पिछले साल की तुलना में 29.7% की बढ़त, पिछली तिमाही की तुलना में 18% की बढ़त।
शुद्ध मुनाफ़ा: ₹37.93 करोड़; पिछले साल की तुलना में 32.1% की गिरावट, पिछली तिमाही की तुलना में 15.5% की गिरावट।
ऑपरेटिंग मार्जिन: 7.2% (एक साल पहले 15.4%)।
EPS: ₹15.17; पिछले साल की तुलना में 32.1% की गिरावट, पिछली तिमाही की तुलना में 15.5% की गिरावट।
ASTRAZENના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹682.79 કરોડ; ગયા વર્ષની સરખામણીએ 29.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 18% વધારો.
ચોખ્ખો નફો: ₹37.93 કરોડ; ગયા વર્ષની સરખામણીએ 32.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 15.5% ઘટાડો.
ઓપરેટિંગ માર્જિન: 7.2% (એક વર્ષ પહેલાં 15.4%).
EPS: ₹15.17; ગયા વર્ષની સરખામણીએ 32.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 15.5% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
13/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 59.3% over the last 20 sessions vs 63.0% in the 40 before (0.94x); shares delivered per day 0.82x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 3/15: 1 scheme hold it, about ₹39 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 37/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 11 Aug 26Results Q1 FY27 results: profit −32.1% YoY -2.3% next session
- 31 Jul 26Dividend Dividend ₹36 (ex-date) +2.5% next session
- 26 May 26Results Q4 FY26 results: profit −23.0% YoY -1.7% next session
- 11 Feb 26Results Q3 FY26 results: profit +5.6% YoY -1.5% next session
- 7 Nov 25Results Q2 FY26 results: profit +41.1% YoY -1.1% next session
- 14 Aug 25Results Q1 FY26 results: turned to profit vs a year ago 0.0% next session
- 18 Jul 25Dividend Dividend ₹32 (ex-date) -2.7% next session
- 30 May 25Results Q4 FY25 results: profit +47.5% YoY +17.9% next session
- 11 Feb 25Results Q3 FY25 results: profit +95.3% YoY -0.6% next session
- 14 Nov 24Results Q2 FY25 results: profit −26.6% YoY -10.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹683 cr | ₹38 cr | -32.1% | 7.2% | 15.17 |
| Mar 2026 | ₹579 cr | ₹45 cr | -23.0% | 10.5% | 17.95 |
| Dec 2025 | ₹612 cr | ₹33 cr | +5.6% | 7.3% | 13.04 |
| Sept 2025 | ₹559 cr | ₹54 cr | +41.1% | 13.4% | 21.69 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions (FII) | 2.64% | 2.68% | 2.78% | 2.71% |
| Domestic institutions (DII) | 7.09% | 6.08% | 5.80% | 5.56% |
| Mutual funds | 7.01% | 6.01% | 5.66% | 5.43% |
| Retail investors | 7.70% | 7.65% | 7.70% | 7.51% |
| Number of shareholders | 30,408 | 29,338 | 29,007 | 31,551 |
Common questions
What was AstraZeneca Pharma India Limited's latest quarterly profit?
AstraZeneca Pharma India Limited reported a net profit of ₹38 cr for the quarter ended Jun 2026 (-32.1% on the same quarter a year earlier), on revenue of ₹683 cr.
How much do promoters hold in AstraZeneca Pharma India Limited?
Promoters held 75.00% of AstraZeneca Pharma India Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is AstraZeneca Pharma India Limited debt-free?
Its latest reported debt-to-equity ratio is 0.13.
What is AstraZeneca Pharma India Limited's P/E ratio?
About 93.8, based on the last 12 months' earnings and a price of ₹6,364.5 (data 2026-11-01).
What is the 52-week high and low of AstraZeneca Pharma India Limited?
The 52-week high is ₹9,849.5 and the 52-week low is ₹5,640.
Mutual funds holding AstraZeneca Pharma India Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹39 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 0.42% | ₹39 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharma India Limited | ₹6,364.5 | ₹15,918 cr | 93.8 | — | 23.9% | 25.5% | 0.13 | -31.8% |
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
| Eris Lifesciences Ltd | ₹1,156.4 | ₹16,088 cr | 22.5 | 3.9 | 18.3% | 15.6% | 0.6 | -29.0% |
| Alembic Pharmaceuticals Limited | ₹797.85 | ₹15,682 cr | 22.6 | — | 12.3% | 11.8% | 0.25 | -11.4% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
Compare ASTRAZEN with COHANCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ASTRAZEN in NSE Scanner →